NX Prenatal Inc. has added fresh cash to its coffers — and it’s looking for more.
The Louisville-based health care startup has raised $3.1 million of a $15 million offering, according to a U.S. Securities and Exchange Commission filing.
It’s not immediately clear what the funds will be used for or if NX Prenatal plans to raise the remaining $11.9 million left in the offering. CEO Brian Brohman did not return a request for comment.
The new funding comes two years after NX Prenatal raised nearly $5 million, bringing its lifetime capital raised to $10.7 million, according to SEC filings.
NX Prenatal develops diagnostic tests for adverse pregnancy conditions such as preterm birth, preeclampsia and placenta accreta, according to the company’s website. The tests are designed to give physicians time to intervene and attempt to reduce possible complications for the baby and the mother.
The startup was spun out of Louisville-based life sciences company NX PharmaGen Inc., along with Nexosome Oncology and NX Development Corp.
NX Development Corp. also raised $4 million and fostered the Food & Drug Administration approval and U.S. launch of a new imaging tool for brain tumor patients before it was acquired in 2018.
In other Louisville startup funding news, Untitled Firm, a data-management firm, recently raised $2.8 million of a $3.75 million "seed-plus" round. And in early August, KY Inno reported Forecastr, a Software-as-a-Service business that helps startups forecast revenue, raised $4.5 million in new capital. GoodMaps won $1 million at Rally, an innovation conference in Indianapolis, at the end of last month.
